BioStock: Circio's CEO on the new strategy

Circio, formerly known as Targovax, is a Norwegian immunotherapy company within RNA-based therapeutics. The company is focusing on circular RNA, which holds several advantages over mRNA, according to CEO Erik Digman Wiklund. The potential of circular RNA has been acknowledged by the industry, as the area is attracting a lot of interest and investments.

Watch the interview with Circio's CEO Erik Digman Wiklund at biostock.se.

https://www.biostock.se/en/2023/05/circios-ceo-on-the-new-strategy/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/